SARS-CoV-19 Preprints

Primary and secondary outcomes comparison found differences not to be statistically significant

French team finds #Hydroxychloroquine ineffective in treating hospitalized #COVID19 patients with #SARSCoV2-positive hypoxic pneumonia medrxiv.org/content/10.110… @AlexAndersonMD @DrMJoyner @cshperspectives @VPrasadMDMPH @vincentRK @ACasadevall1 #NovelCoronavirus #coronavirus

3/3 Figure 2 depicts disease progression for convalescent plasma treatment of three patients - two successful cases and one failed case involving adverse response to injection

1/3 Preprint out of Hunan Province, China outlines Chinese strategy in #ConvalescentPlasma therapy for #COVID19 - medrxiv.org/content/10.110… @AlexAndersonMD @DrMJoyner @cshperspectives @VPrasadMDMPH @vincentRK @ACasadevall1 #NovelCoronavirus #coronavirus #SARSCoV2

2/3 Figure 1 depicts flow chart of Chinese protocols for recovered donor recruitment, plasma collection, plasma examination, and administration of convalescent plasma therapy

This is good news indeed. What does the curve for NYC look like ?

A lot of people are wondering why #Japan has so few cases of #COVID19. In this commentary, @NathanGrubaugh and I speculate on some possible reasons. (1/n) embopress.org/doi/10.15252/e…

Excellent video from @WSJ explaining how convalescent plasma against #COVID19 would work. wsj.com/video/why-bloo…

I made a Table on the striking differences in COVID deaths in 6 countries 1) Case fatality rate differences partly explained by testing frequency: except Italy— reflects overwhelmed system? 2) Deaths/million: likely reflects extent of spread in a country @PSampathkumarMD @choo_ek

New results from a (small) pilot study of convalescent plasma therapy for COVID-19: pnas.org/content/early/… Published without embargo due to immediate relevance. PNAS ⬇️

@nrgruski @kevincmiller13 Possibly, but this preprint highlights a potential reason for this higher titer being a potentially impaired T-cell response. More must be done to investigate here. Additionally, this data provides insights on best targets for plasma donors.

@SARSCoV192 @kevincmiller13 So A 60-85 develop highest titers? Is that not a good thing?

1/11 Analysis of humoral immune response in #COVID19 patients provides key insights for #ConvalescentPlasma therapy and #Vaccine research: medrxiv.org/content/10.110…

11/11 Concerns, commentary, and questions welcomed at this crucial stage of the #ConvalescentPlasma therapy effort @CCPP19 @ACasadevall1 @AlexAndersonMD @DrMJoyner @cshperspectives @VPrasadMDMPH @vincentRK @medrxivpreprint #coronavirus

10/11 Limitations: -Current lack of peer review (pre-print) -Lack of information about the kinetics of viral loads (lacked respiratory specimens) -Patients in severe and critical condition were excluded from the study (received passive antibody treatment before sample collection)

9/11 Despite 77.2% identical amino acids between SARS-CoV-2 and SARS-CoV spike proteins and cross-binding potential, COVID-19 convalescent plasma did NOT neturalize SARS-CoV, suggesting differences between #SARSCoV2 and #SARSCoV #epitopes and #immunogenicity

8/11 NAb titers negatively correlated with blood lymphocyte counts and positively correlated with blood CRP levels, suggesting that the humoral response might play an important role when cellular response is dysfunctional or impaired.

7/11 NAb titers in ten of the 175 recovered patients were below limit of detection despite lab-confirmed infection with SARS-CoV-2

6/11 Neutralizing antibody titers of COVID-19 patients collected two weeks post-discharge did not significantly differ from those collected at the time of discharge

5/11 Temporal analysis of COVID19 antibody titers shows humoral immune response ramping up on day 10-15 post-onset of disease

4/11 Older COVID19-recovered patients demonstrated higher titers of both neutralizing and spike-binding #SARSCoV2-specific #antibodies